ClinicalTrials.gg
CompletedNCT06586216Updated Feb 19, 2025

A Study to Learn How Renal Impairment Affects the Pharmacokinetics of PF-07817883.

A Phase 1 interventional study of PF-07817883 in COVID-19, sponsored by Pfizer. Completed at 3 sites in United States. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-19.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Feb 2025, 1 year 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies in COVID-19 by Pfizer — 4 open to participants now, 10 under way, 3 of them phase 3. COVID-19 · Pfizer.

Enrollment
24th of 41
16 · median 20
Started
2024
with 10 others
Phase 1
25 of 69
none open now
Registered
55th of 69
by date

Among the 69 studies in COVID-19 by Pfizer, this one is the 24th largest by enrollment of the 41 interventional ones that give a count, is one of 11 that started in 2024, is one of 25 in phase 1, and was the 55th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

4 of the 69 studies in COVID-19 by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in COVID-19 by Pfizer, or all of them as a file.
02

Study summary

The purpose of the study is to learn about:

  • how PF-07817883 is processed in the body of adult participants.
  • the safety of PF-07817883.

These participants will have different levels of kidney function loss:

  • moderate
  • severe
  • none or healthy Participants with moderate, severe or no loss of kidney function may be taken into one of 3 groups.

This study is seeking for participants who:

  • are male or female of 18 to 90 years of age.
  • have different levels of damage to kidney function or for one of the groups, no damage
  • are willing to follow the requirements of the study including stay at clinic for 5 nights and 6 days.

About, 8 participants may be selected in groups 2 and 3. In group 1, around 8 to 12 participants may be selected. If participants agree to take part in the study, it may take up to 4 weeks to complete all the tests to confirm if they are fit to be in the study. If they seem to be fit for the study, participants will be admitted to a clinic research unit (CRU) at least 8 hours before dosing.

On Day 1, participants will receive a single amount of study medicine (Day 1). A series of blood samples will be collected before and after giving medicines. Participants will be discharged from the CRU on Day 5. A follow-up phone call (or CRU visit, if needed), will occur 28-35 days after taking the medicine. The whole study will last for a minimum of 5 weeks and a maximum of 10 weeks.

03

Conditions studied

  • COVID-19

Keywords

  • Renal Impairment
  • COVID-19
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants aged 18 (or the minimum age of consent in accordance with local regulations) to 90 years of age at screening.
  • of ≥16 kg/m2 and a total body weight >45 kg (99 lbs).
  • Stable renal function, defined as the values obtained at the two screening visits should not be more than 25% different.

Exclusion criteria

Exclusion Criteria:

  • Positive test result for severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) infection at the time of screening or Day -1.
  • History of (HIV) infection, , or ; positive testing at screening for HIV, hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or hepatitis C antibody (HCVAb). As an exception, a positive hepatitis B surface antibody (HBsAb) test due to hepatitis B vaccination is allowed.
  • Renal transplant recipients.
  • Any condition possibly affecting drug absorption
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Cohort 1

    No renal impairment

    Drug: PF-07817883

  • Experimental
    Cohort 2

    Severe renal impairment

    Drug: PF-07817883

  • Experimental
    Cohort 3

    Moderate renal impairment

    Drug: PF-07817883

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of PF-07817883

    Plasma PF-07817883 PK parameters

    Time frame: Day 1 to Day 5

  2. Area under the Plasma Concentration-time Profile from Time Zero to Extrapolated Infinite Time (AUCinf)

    Plasma PF-07817883 PK parameters

    Time frame: Day 1 to Day 5

  3. Area under the Plasma Concentration-time Profile from Time Zero to the Time of the Last Quantifiable Concentration (AUClast)

    Plasma PF-07817883 parameters

    Time frame: Day 1 to Day 5

Secondary outcomes

  1. Number of participants with Non-Serious Adverse Events (NSAE)

    Safety Parameter

    Time frame: Screening to Day 35

  2. Number of participants with Treatment Emergent Adverse Events

    Safety Parameter

    Time frame: Day 1 to Day 35

  3. Number of participants with Clinically Significant ECG Abnormalities

    Time frame: Day 1 to Day 5

  4. Number of participants with Clinically Significant Abnormal Vital Signs

    Time frame: Day 1 to Day 5

  5. Number of participants with Clinically Significant abnormal laboratory values.

    Time frame: Baseline to Day 5

  6. Number of participants with Serious Adverse Events

    Safety parameters

    Time frame: Screening to Day 35

07

Study locations

3 sites
  • Clinical Pharmacology of Miami
    Miami, Florida 33014, United States
  • Genesis Clinical Research, LLC
    Tampa, Florida 33603, United States
  • Prism Research LLC dba Nucleus Network
    Saint Paul, Minnesota 55114, United States
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Feb 2025, 5 months.

Of 233 industry-sponsored phase 1 interventional studies under COVID-19, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's 5 months is below that.

Counting every sponsor, half of 384 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2024
First posted
Sep 19, 2024
StartActual
Sep 10, 2024
Primary completionActual
Feb 13, 2025
CompletionActual
Feb 13, 2025
Last update
Feb 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06586216
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Sep 10, 2024
Primary completion
Feb 13, 2025
Completion
Feb 13, 2025
Last update
Feb 19, 2025

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuzatrelvir

Start the discussion